Dr. Christopher Perkins, MD

Hematology & Oncology Fresno, CA Male
NPI: 1396820189
Total Payments
$15,854
2023 Payments
$864.36
Companies
43
Transactions
427
Medicare Patients
44,150
Medicare Billing
$4.6M

Payment Breakdown by Category

Food & Beverage$7,729 (48.8%)
Consulting$5,694 (35.9%)
Research$2,065 (13.0%)
Travel$255.12 (1.6%)
Education$110.82 (0.7%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $7,729 415 48.8%
Consulting Fee $5,694 3 35.9%
Unspecified $2,065 2 13.0%
Travel and Lodging $255.12 1 1.6%
Education $110.82 6 0.7%

Payments by Type

General
$13,789
425 transactions
Research
$2,065
2 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $5,340 55 $0 (2023)
Eli Lilly and Company $2,065 2 $0 (2023)
Daiichi Sankyo Inc. $1,638 85 $0 (2023)
TESARO, Inc. $1,054 5 $0 (2019)
AstraZeneca Pharmaceuticals LP $671.68 35 $0 (2023)
PUMA BIOTECHNOLOGY, INC. $501.29 28 $0 (2022)
Lilly USA, LLC $473.30 29 $0 (2021)
Merck Sharp & Dohme LLC $465.09 26 $0 (2022)
GlaxoSmithKline, LLC. $332.96 15 $0 (2022)
EISAI INC. $307.11 17 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2023 $864.36 5 Eli Lilly and Company ($724.26)
2022 $3,085 68 Eli Lilly and Company ($1,341)
2021 $1,706 101 Daiichi Sankyo Inc. ($346.17)
2020 $1,502 92 Daiichi Sankyo Inc. ($326.29)
2019 $4,811 47 PFIZER INC. ($4,109)
2018 $1,782 57 PFIZER INC. ($778.22)
2017 $2,104 57 TESARO, Inc. ($1,024)

All Payment Transactions

427 individual payment records from CMS Open Payments — Page 1 of 18

Date Company Product Nature Form Amount Type
04/19/2023 Daiichi Sankyo Inc. Enhertu (Drug) Food and Beverage In-kind items and services $21.13 General
Category: ONCOLOGY
02/16/2023 PFIZER INC. IBRANCE (Drug) Food and Beverage In-kind items and services $75.75 General
Category: ONCOLOGY
02/08/2023 Eli Lilly and Company — — In-kind items and services $724.26 Research
Study: EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE
02/08/2023 Celgene Corporation OPDUALAG (Drug) Food and Beverage Cash or cash equivalent $18.90 General
Category: Oncology
01/13/2023 AstraZeneca Pharmaceuticals LP ENHERTU (Biological) Food and Beverage In-kind items and services $24.32 General
Category: Oncology
12/15/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $22.93 General
Category: ONCOLOGY
12/15/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $3.41 General
Category: ONCOLOGY
12/14/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $1.00 General
Category: ONCOLOGY
12/09/2022 AstraZeneca Pharmaceuticals LP LYNPARZA (Drug) Food and Beverage In-kind items and services $16.39 General
Category: Oncology
11/28/2022 PFIZER INC. IBRANCE (Drug), COMIRNATY, PAXLOVID Food and Beverage In-kind items and services $16.93 General
Category: ONCOLOGY
11/22/2022 Merck Sharp & Dohme LLC KEYTRUDA (Biological), LYNPARZA Food and Beverage In-kind items and services $16.31 General
Category: ONCOLOGY
11/16/2022 Eli Lilly and Company — — In-kind items and services $1,341.00 Research
Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE
11/16/2022 AstraZeneca Pharmaceuticals LP ENHERTU (Biological) Food and Beverage In-kind items and services $24.44 General
Category: Oncology
11/07/2022 Gilead Sciences, Inc. Trodelvy (Drug) Food and Beverage In-kind items and services $3.65 General
Category: ONC
11/06/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $0.71 General
Category: ONCOLOGY
10/26/2022 Seagen Inc. TUKYSA (Drug) Food and Beverage In-kind items and services $13.64 General
Category: Oncology
10/19/2022 Merck Sharp & Dohme LLC KEYTRUDA (Biological), LYNPARZA Food and Beverage In-kind items and services $19.84 General
Category: ONCOLOGY
10/05/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $2.68 General
Category: ONCOLOGY
10/04/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $13.24 General
Category: ONCOLOGY
10/04/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $0.89 General
Category: ONCOLOGY
10/03/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $1.52 General
Category: ONCOLOGY
09/29/2022 Amgen Inc. XGEVA (Biological) Food and Beverage In-kind items and services $16.64 General
Category: Oncology
09/21/2022 Merck Sharp & Dohme LLC KEYTRUDA (Biological), LYNPARZA Food and Beverage In-kind items and services $14.67 General
Category: ONCOLOGY
09/14/2022 Gilead Sciences, Inc. Trodelvy (Drug) Food and Beverage In-kind items and services $18.42 General
Category: ONC
09/12/2022 Daiichi Sankyo Inc. ENHERTU (Drug) Food and Beverage In-kind items and services $23.77 General
Category: ONCOLOGY
123…18»

Research Studies & Clinical Trials

Study Name Company Amount Records
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE Eli Lilly and Company $1,341 1
EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE Eli Lilly and Company $724.26 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2022 50 9,769 66,269 $3.6M $745,150
2021 54 11,950 134,855 $4.8M $1.2M
2020 69 22,431 172,215 $8.9M $2.7M
Total Patients
44,150
Total Services
373,339
Medicare Billing
$4.6M
Procedure Codes
173

All Medicare Procedures & Services

173 procedure records from CMS Medicare Utilization — Page 1 of 7

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
J0897 Injection, denosumab, 1 mg Office 2022 48 19,320 $1.2M $331,359 28.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 572 1,065 $431,325 $98,639 22.9%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 543 1,036 $295,500 $67,315 22.8%
96413 Administration of chemotherapy into vein, 1 hour or less Office 2022 45 276 $129,168 $31,381 24.3%
J9395 Injection, fulvestrant, 25 mg Office 2022 23 2,540 $368,300 $26,327 7.1%
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 Office 2022 613 966 $82,110 $19,803 24.1%
82378 Carcinoembryonic antigen (cea) protein level Office 2022 621 955 $73,535 $17,871 24.3%
80053 Blood test, comprehensive group of blood chemicals Office 2022 874 1,692 $72,756 $17,601 24.2%
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units Office 2022 21 2,640 $73,920 $17,088 23.1%
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count Office 2022 904 2,078 $66,496 $15,860 23.9%
82977 Glutamyltransferase (liver enzyme) level Office 2022 710 1,154 $33,466 $8,221 24.6%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 47 63 $35,656 $8,019 22.5%
83540 Iron level Office 2022 724 1,170 $30,420 $7,468 24.5%
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2022 25 266 $27,872 $7,304 26.2%
83615 Lactate dehydrogenase (enzyme) level Office 2022 724 1,168 $29,200 $6,969 23.9%
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less Office 2022 44 252 $25,452 $6,389 25.1%
96417 Administration of additional new drug or substance into vein, 1 hour or less Office 2022 22 110 $24,970 $6,305 25.2%
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Office 2022 12 8,160 $89,760 $6,131 6.8%
84100 Phosphate level Office 2022 724 1,168 $22,192 $5,468 24.6%
84550 Uric acid level, blood Office 2022 724 1,167 $21,006 $5,199 24.8%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 32 32 $22,016 $4,786 21.7%
36415 Insertion of needle into vein for collection of blood sample Office 2022 693 1,176 $27,048 $3,480 12.9%
96372 Injection of drug or substance under skin or into muscle Office 2022 69 286 $19,734 $3,367 17.1%
96375 Injection of additional new drug or substance into vein Office 2022 41 222 $13,414 $2,993 22.3%
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less Office 2022 39 54 $12,397 $2,936 23.7%
123…7»

About Dr. Christopher Perkins, MD

Dr. Christopher Perkins, MD is a Hematology & Oncology healthcare provider based in Fresno, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396820189.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Perkins, MD has received a total of $15,854 in payments from pharmaceutical and medical device companies, with $864.36 received in 2023. These payments were reported across 427 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($7,729).

As a Medicare-enrolled provider, Perkins has provided services to 44,150 Medicare beneficiaries, totaling 373,339 services with total Medicare billing of $4.6M. Data is available for 3 years (2020–2022), covering 173 distinct procedure/service records.

Practice Information

  • Specialty Hematology & Oncology
  • Location Fresno, CA
  • Active Since 10/27/2006
  • Last Updated 07/14/2008
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • NPI Number 1396820189

Products in Payments

  • IBRANCE (Drug) $4,644
  • VARUBI (Drug) $1,092
  • ENHERTU (Drug) $923.27
  • Enhertu (Drug) $610.62
  • KEYTRUDA (Biological) $448.11
  • LYNPARZA (Drug) $375.70
  • ZEJULA (Drug) $334.76
  • NERLYNX (Drug) $305.89
  • SIR-Spheres Microspheres (Device) $284.33
  • KISQALI (Drug) $271.77
  • CYRAMZA (Drug) $268.06
  • FOUNDATIONONE (Device) $259.32
  • TUKYSA (Drug) $203.04
  • Lenvima (Drug) $201.84
  • Nerlynx (Drug) $195.40
  • Trodelvy (Drug) $187.38
  • Cabometyx (Drug) $158.84
  • VERZENIO (Drug) $151.53
  • Perjeta (Biological) $150.77
  • SANCUSO (Drug) $127.19

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Fresno

Dr. Steven Hager, D.o, D.O

Hematology & Oncology — Payments: $146,431

Hematology & Oncology $146,431

Dr. Abdul Haseeb, M.d, M.D

Hematology & Oncology — Payments: $142,588

Hematology & Oncology $142,588

Ravi Rao, Md, MD

Hematology & Oncology — Payments: $87,108

Hematology & Oncology $87,108

Dr. Rabia Parveez, Md, MD

Hematology & Oncology — Payments: $26,868

Hematology & Oncology $26,868

Dexter Estrada, M.d, M.D

Hematology & Oncology — Payments: $15,528

Hematology & Oncology $15,528

Dr. William Jawien, Md, MD

Hematology & Oncology — Payments: $15,203

Hematology & Oncology $15,203